Rasagiline

The elevated striatal dopamine levels induced by rasagiline-dependent MAO-B inhibition has been correlated to improvements in PD motor symptoms in both monotherapy and adjunctive therapy studies. The TEMPO (TVP-2012 in Early Monotherapy for Parkinson’s Disease Outpatients) study, a 26-week, randomized, double-blind and placebo-controlled clinical trial observed the efficacy of rasagiline as a monotherapy for 404 early PD patients. Efficacy of rasagiline was quantified using the Unified Parkinson’s Disease

dispense rasagiline (Azilect) to her. I will tell her that rasagiline is helpful in controlling her Parkinson's disease. The instruction is to take 1 tablet by mouth daily. If she needs to use the EpiPen, use it because it is lifesaving, although she might be experiencing severe and prolonged hypertension symptoms. Informing the medical assistance people that she takes rasagiline and Lisinopril daily, so they would know that they need to carefully monitor blood pressure for her. Rasagiline may cause

Parkinson’s disease (PD) is a striatal dopamine deficiency disorder as a consequence of neuronal loss in the substania nigra. It is named after James Parkinson, a British apothecary, who first fully documented its physical signs in 1817. Since then, significant advances have been made in our understanding of characteristic pathophysiology as well as in the medical treatment of different stages of PD. An overview of condition features in terms of epidemiology, manifestations, diagnosis and disease

often 6 times a day instead of four times a day (1). The duration of action of carbidopa-levodopa is shorter which is effective in one hour; it cuts the chances of wearing off effect and increases the “on” time effect. In addition, MAO-B inhibitors (rasagiline) extend the effectiveness of carbidopa-levodopa. Patient is facing tremor in her upper extremities, which is also another complication of levodopa therapy. Dyskinesia can be seen with higher and lower dose of levodopa. At higher dose of dyskinesia

CONTENTS 1. Introduction 2. Aim and objective of the work 3. Plan of work 4. Materials and Method 5. Results and discussion 6. References 1. INTRODUCTION The main goal of pharmaceutical formulation is to achieve better therapeutic activity in the shortest possible time by using smallest quantity of drug administered by the most suitable route. Oral drug delivery is the simplest and easiest way of administering drugs, Because of the greater stability, smaller bulk, accurate dosage

There are many treatments out there now like medication, therapy, surgery, and clinical trials. All these treatments are aimed to increase the level of dopamine in the system. There are many different medications out there that are used for PD patients. These are Carbidopa-levodopa, Carbidopa-levodopa Infusions, Dopamine agonists, MAO-B Inhibitors, Catechol-O-methyltransferase (COMT) Inhibitors, Anticholinergics, and Amantadine. There are many pros and cons to these medications the side effects that

dental team should guard against, especially with COMT inhibitors. Inside the brain, dopamine is broken down by the monoamine oxidase type- B enzyme. Therefore MAO-B inhibitors are used to retain the body's available dopamine as much as possible. Rasagiline and selegiline are used in this way. Anticholinergic drugs help to deal with the increased salivary production and drooling Parkinson's Disease can cause. Tremors, also, are treated this way. Side effects of these include xerostomia, urinary retention

PARKINSON'S DISEASE Parkinson also known as idiopathic Parkinson basically targets dopamine in brain nerve cells specially in mid brain and substantia nigra causes cell death. In Parkinson disorder levels of dopamine are decreased in brain. In early stage of Parkinson signs are very oblivious which includes tremors (shaking of hands), muscle rigidity and slowness of movement. Treatment can relief the symptoms but do not cure the disease. CLASSIFICATION: 1. IDIOPATHIC PARKINSON'S DISEASE: In

Introduction Parkinson 's disease (PD) is the second world 's major neurological disease (Laut & Breteler, 2006) affecting 6 million people globally (Schapira, 1999). PD is a progressive and long term disorder of the central nervous system (CNS) activity with the following traits including bradykinesia, rigorousness, involuntary muscular contraction and unstable postural alignment (O ' Sullivan & Schmitz, 2007). Basal ganglia are located in the CNS have large nerve fibers and neurotransmitters

Introduction of Clinical Question In a normal brain neurons in the substantia nigra produce a chemical called dopamine that acts to control motor functions. In a person with Parkinson’s disease, there is insufficient dopamine and motor symptoms such as tremors, rigidity, problems with balance and bradykinesia can occur. According to the National Parkinson Foundation, four to six million people worldwide are estimated to have Parkinson’s Disease. In the United States alone, the incidence is estimated